Showing 2611-2620 of 8209 results for "".
Joel Schlessinger MD Explains How a Spa Helped Build His Practice
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-explains-how-a-spa-helped-build-his-practice-/19156/As the dermatology and skin care industry expands, the opportunity to offer new procedures, techniques and products for your patients grows. One way that Joel Schlessinger MD chose to advance his business was by adding a spa on to his current practice. In this video, he explains how the decision helSilk Peel Video
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/silk-peel-video/19443/Video describing the advantages of using the SilkPeel Dermalinfusion for facial rejuvenation.New Hope for the Hopeless
https://practicaldermatology.com/issues/august-2025/new-hope-jak-inhibitors-alopecia/36693/Dr. Elizabeth (Lisa) Swanson, a dermatologist and associate medical editor of Practical Dermatology, looks at the critical role of case reports in developing new therapeutic options for patients.The Biosimilar Revolution: A Look at the Potential Impact
https://practicaldermatology.com/issues/april-2025/the-biosimilar-revolution-a-look-at-the-potential-impact/35596/With many biosimilars expected to gain regulatory approval in coming months and years, Practical Dermatology interviewed Collin Blattner, DO, FAAD—an editorial board member and double-board–certified dermatologist who owns Clearchoice Dermatology, which has 12 locations in Oregon and Washington—abouSkin Coverage as a Medical Benefit
https://practicaldermatology.com/series/c-suite-chats/skin-coverage-as-a-medical-benefit/35559/Mike Jafar, Founder and CEO of Joya Health, talks about the importance of having skin coverage as a medical benefit, trends in dermatology, and the driver behind the rising rates of melanoma.Addressing Equity Gaps in Psoriasis Research
https://practicaldermatology.com/series/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.Nemluvio Gains Two Major Indications in Europe
https://practicaldermatology.com/series/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.Making Hair Care Safer for Skin
https://practicaldermatology.com/series/c-suite-chats/making-hair-care-safer-for-skin/32711/Iris Rubin, Founder and Chief Medical Officer of SEEN, discusses how hair care products can cause a variety of skin issues, and the process in which she developed SEEN hair care.Improving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/series/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Chronic Hand Eczema Treatment Landscape
https://practicaldermatology.com/series/c-suite-chats/chronic-hand-eczema-treatment-landscape/29126/Jacob Thyssen, MD, PhD, Chief Scientific Officer at Leo Pharma, talks about the incidence of chronic hand eczema and the advantage that delgocitinib provides compared to other treatment options.